Myelodysplastic Syndromes: all 2,165 studies
Page 18 of 22. Open to participants first (322), then studies with results posted, then the rest; newest registration first within each.
- Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)CompletedNCT00854646Phase 1
- Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute LeukemiasTerminatedNCT00852709Phase 1
- Study of Stem Cell Transplant for Leukemia and Myelodysplastic Syndromes Using Clofarabine and Busulfan RegimenCompletedNCT00852163Phase 2
- Early Discharge and Outpatient Care After Chemotherapy in Patients With Myelodysplastic Syndrome or Acute Myeloid LeukemiaCompletedNCT00844441Not applicable
- Immunotherapy Using Lenalidomide + Bystander Vaccine in High Risk Myelodysplastic Syndrome (MDS)CompletedNCT00840931Phase 1
- Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk MyelodysplasiaStatus unknownNCT00838240Phase 1/2
- Lenalidomide and Decitabine in High Grade Myelodysplastic SyndromesCompletedNCT00828802Phase 1
- Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced CancerCompletedNCT00823524Phase 1/2
- Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)CompletedNCT00822393Phase 3
- RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDSActive, not recruitingNCT00819546Phase 1
- Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological CancerWithdrawnNCT00816413Phase 1/2
- Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other DiseasesTerminatedNCT00813501
- Quality of Life and Symptoms in Patients With Newly Diagnosed Myelodysplastic SyndromesStatus unknownNCT00809575
- Collection and Banking of Leukemia Cells MDS/AMLCompletedNCT00809367Not applicable
- Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell TransplantationCompletedNCT00809250Phase 1
- A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic MalignanciesCompletedNCT00807677Phase 1
- Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological CancerCompletedNCT00806767Phase 2
- Multicentric Study Comparison Between Erythropoietin and Erythropoietin Associated to Differentiating Therapy With Acid 13-cis-retinoic and Dihydroxyvitamin D3 in Myelodysplastic Syndromes Without Excess of BlastsTerminatedNCT00804050Phase 3
- Study of Association of Arsenic Trioxide (ATO) and Ascorbic Acid in Myelodysplastic SyndromesTerminatedNCT00803530Phase 2
- Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to TreatmentTerminatedNCT00800150Phase 1
- Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late ComplicationsCompletedNCT00799461Phase 3
- Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell TransplantationCompletedNCT00795548Phase 2
- A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their FamiliesCompletedNCT00782145Phase 3
- Vorinostat and Low Dose Cytarabine for High Risk MyelodysplasiaCompletedNCT00776503Phase 1/2
- Busulfan Plus Cyclophosphamide vs Fludarabine as a Conditioning RegimenCompletedNCT00774280Phase 3
- Perceptions of Burden in Patients With Late-Stage Cancer and Their CaregiversWithdrawnNCT00770419
- Blood Samples to Evaluate Biomarkers of Donor ChimerismCompletedNCT00764829
- Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple MyelomaCompletedNCT00761722Phase 1
- A Study of Oral Clofarabine in Adult Patients With Myelodysplastic Syndromes (MDS)TerminatedNCT00750334Phase 1
- Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical TrialCompletedNCT00750009Phase 3
- MRI Screening for Patients With Myelodysplastic Syndrome (MDS), Who Have Received Multiple Red Blood Cell TransfusionsCompletedNCT00749372Not applicable
- Efficacy Study of Revlimid® and Low Dose Continuously Administered Melphalan to Treat High Risk MDSCompletedNCT00744536Phase 2
- A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With AzacitidineCompletedNCT00741234Phase 1
- Centralized Cord Blood Registry to Facilitate Unrelated Cord Blood TransplantationCompletedNCT00737516Phase 2
- Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematologic Cancer or Myelodysplastic SyndromeCompletedNCT00732316Phase 2
- Donor Stem Cell Transplant After Busulfan, Fludarabine, Methylprednisolone, and Antithymocyte Globulin in Treating Patients With Bone Marrow Failure SyndromeCompletedNCT00731328Phase 2
- Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell TransplantTerminatedNCT00725062Phase 1
- The Role of Erythropoietin in Myelodysplastic SyndromeCompletedNCT00723112
- Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)TerminatedNCT00720850Phase 2
- A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid MalignanciesCompletedNCT00719836Phase 1/2
- Measuring Changes in Blood in Patients at High Risk of Cytomegalovirus Infection After Undergoing Donor Bone Marrow Transplant or Peripheral Blood Stem Cell TransplantCompletedNCT00716911Not applicable
- CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide GeneActive, not recruitingNCT00710892Phase 1
- Safety and Efficacy of Azacitidine, and Thalidomide in Higher Risk MDS (Myelodysplastic Syndrome)Status unknownNCT00704704Phase 2
- Phase 2 Study Comparing Two Dose Schedules of Telintra™ in Myelodysplastic Syndrome (MDS)CompletedNCT00700206Phase 2
- Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell TransplantCompletedNCT00697684Phase 1
- Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic MalignanciesCompletedNCT00697671Phase 1
- Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM)CompletedNCT00689000Phase 1/2
- Total Marrow Irradiation for Refractory Acute LeukemiaCompletedNCT00686556Phase 1
- Serial Analysis of Chimerism in Patients With Refractory Cytopenia (RC) Transplanted With Reduced Intensity Conditioning (RIC)CompletedNCT00682799
- Safety Study of MultiStem® in Patients With Acute Leukemia, Chronic Myeloid Leukemia, or MyelodysplasiaCompletedNCT00677859Phase 1
- A Study of the Histone-deacetylase Inhibitor JNJ-26481585 in Patients With Advanced or Refractory Leukemia or Myelodysplastic SyndromeTerminatedNCT00676728Phase 1
- Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell TransplantTerminatedNCT00674427Phase 1
- Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron OverloadCompletedNCT00673608Phase 4
- Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid MalignanciesCompletedNCT00672165Phase 1
- A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following TransplantationTerminatedNCT00672152Phase 1
- Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid LeukemiaCompletedNCT00671697Phase 1
- Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMMLTerminatedNCT00669890Phase 1
- Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)TerminatedNCT00666497Phase 2
- Phase 1 Study of Terameprocol (EM-1421) in Patients With LeukemiaTerminatedNCT00664677Phase 1
- Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional CytarabineTerminatedNCT00655395Phase 1/2
- T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell TransplantTerminatedNCT00651716
- Clofarabine and High-Dose Melphalan Followed by Donor Stem Cell Transplant in Patients With Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Myelodysplastic SyndromesCompletedNCT00641030Phase 1
- Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid TumorsCompletedNCT00640796Phase 1
- Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematological CancerCompletedNCT00627666Phase 2
- Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromesCompletedNCT00624936Phase 1
- Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell TransplantationCompletedNCT00620633Phase 1
- Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12 in Treating Patients With Advanced LeukemiaTerminatedNCT00618696Phase 1
- Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) TransplantsCompletedNCT00606437Phase 1
- Structural Imaging and Cognitive Functions in Adult Stem Cell Transplant Recipients Treated With Chemotherapy Alone or in Combination With RadiotherapyCompletedNCT00606216
- T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic CancerCompletedNCT00602693Phase 1
- A Prospective, Multicentre European Registry for Newly Diagnosed Patients With Myelodysplastic SyndromesStatus unknownNCT00600860
- Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)Status unknownNCT00598624Phase 2
- A Phase I Trial of ZIO-101 in Hematologic CancersCompletedNCT00592046Phase 1
- Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative DisordersCompletedNCT00588991Phase 1
- A Phase 1 Dose Escalating Trial of Bortezomib in Combination With Lenalidomide in Patients With MyelodysplasiaCompletedNCT00580242Phase 1
- Palifermin After Haploidentical PBSCTWithdrawnNCT00570999Phase 2
- The Role of Erlotinib an Epidermal Growth Factor Receptor (EGFR) Inhibitor in the Treatment of Myelodysplastic SyndromeWithdrawnNCT00570375Phase 2
- Investigation of the Cylex® ImmuKnow® AssayCompletedNCT00569842
- A Phase I Trial of Alloreactive Cell Infusion Following Transplantation of Haplotype Cells in Patients With Myeloid MalignanciesTerminatedNCT00569179Phase 1
- A Trial of Bevacizumab in Myelodysplastic Syndromes (Int-1, Int-2 and High Risk According to International Prognostic Scoring System (IPSS)) With Excess of Marrow BlastsTerminatedNCT00565656Phase 2
- Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron OverloadCompletedNCT00564941Phase 4
- Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic DisordersCompletedNCT00533923Phase 2
- Safety of ON 01910.Na in Patients With MyelodysplasiaCompletedNCT00533416Phase 1
- Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous LeukemiaCompletedNCT00528983Phase 1
- Molecular Epidemiology of Therapy-related Acute Myeloid Leukemia/Myelodysplastic Syndrome (AML/MDS)Active, not recruitingNCT00525746
- Study to Assess the Safety of Escalating Doses of AT9283, in Patients With LeukemiasTerminatedNCT00522990Phase 1/2
- Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other DiseaseCompletedNCT00521430Not applicable
- Sorafenib and Low Dose Cytarabine in Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeCompletedNCT00516828Phase 1/2
- Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic SyndromeStatus unknownNCT00513578Phase 2
- Unrelated Stem Cell Transplantation for Adults With Hematopoietic DisordersCompletedNCT00511537
- Abdominal Obesity and Cardiovascular Risk Factors in Women Who Survived Cancer or a Related Illness Following Total Body Irradiation and Stem Cell TransplantCompletedNCT00510315
- A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic MalignanciesCompletedNCT00506402Phase 1
- Symptom-Related Cytokines in Acute Myeloblastic Leukemia and Myelodysplastic Syndrome PatientsCompletedNCT00504920
- A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)CompletedNCT00502112Phase 1
- Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With CancerWithdrawnNCT00499668Not applicable
- Assessing Immune Function in Young Patients With Cytopenia That Did Not Respond to TreatmentCompletedNCT00499070
- Cord Blood Expansion on Mesenchymal Stem CellsCompletedNCT00498316Phase 1
- SIMIDIS: Azacitidine and Beta Erythropoietin Treatment in Patients With Myelodysplastic SyndromeTerminatedNCT00495547Phase 2
- Phase I Study of Gimatecan in Patients With Myelodysplastic SyndromesCompletedNCT00493571Phase 1
- Treosulfan-based Conditioning for Transplantation in AML/MDSCompletedNCT00491634Phase 2